Lytix Biopharma (LYTIX) Study Update summary

Study design and objectives

• Phase II study evaluated LTX-315 in patients with basal cell carcinoma (BCC), the most common skin cancer globally.

• Preliminary results were based on data from 93 patients, focusing on efficacy and safety.

• The study aims to position LTX-315 as a potential first-line therapy for BCC.

Key results and findings

• Achieved 86% overall reduction in tumor size and 51% complete clearance rate in BCC patients.

• Patients with residual carcinomas saw a 71% average reduction in tumor size.

• No severe adverse events were reported, indicating a highly favorable safety profile.

Market and commercial implications

• BCC represents a large market, with a projected global size of $11.5 billion by 2028 and 3.6 million new US cases annually.

• Lytix may receive up to $110 million in milestone payments and tiered royalties from Verrica under the license agreement.

• Verrica has experience commercializing dermatology drugs, supporting LTX-315's path to market.